Syncona Limited Notice of Capital Markets Day (4402A)

TIDMSYNC

RNS Number : 4402A

Syncona Limited

21 January 2020

Syncona Limited

Notice of Capital Markets Day

21 January 2020

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, will host a Capital Markets Day for investors and analysts on the afternoon of Tuesday, 4 February 2020 in Central London.

Syncona's management team will present Syncona's strategy and long-term vision for the business. This will be followed by panel discussions with leaders from Syncona's portfolio companies on translating exceptional science, the future of cell therapy, and building a commercial gene therapy platform.

Presentations and panels are taking place from 13:00 - 17:00 GMT. A live webcast of the Capital Markets Day will be made available on the Investor Relations section of the company's website at www.synconaltd.com

For further information and to register to attend, please contact events@synconaltd.com.

[ENDS]

Enquiries

Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel : +44 (0) 20 3981 7940

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

About Syncona

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCVFLBLBFLZBBB

(END) Dow Jones Newswires

January 21, 2020 03:45 ET (08:45 GMT)

Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024